Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years

Detalles Bibliográficos
Autores principales: Olliaro, Piero L., Kuesel, Annette C., Halleux, Christine M., Sullivan, Mark, Reeder, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Viewpoints
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237288/
https://www.ncbi.nlm.nih.gov/pubmed/30439940
http://dx.doi.org/10.1371/journal.pntd.0006837
_version_ 1783371164054192128
author Olliaro, Piero L.
Kuesel, Annette C.
Halleux, Christine M.
Sullivan, Mark
Reeder, John C.
author_facet Olliaro, Piero L.
Kuesel, Annette C.
Halleux, Christine M.
Sullivan, Mark
Reeder, John C.
author_sort Olliaro, Piero L.
collection PubMed
description
format Online
Article
Text
id pubmed-6237288
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-62372882018-12-01 Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years Olliaro, Piero L. Kuesel, Annette C. Halleux, Christine M. Sullivan, Mark Reeder, John C. PLoS Negl Trop Dis Viewpoints Public Library of Science 2018-11-15 /pmc/articles/PMC6237288/ /pubmed/30439940 http://dx.doi.org/10.1371/journal.pntd.0006837 Text en © 2018 Olliaro et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Viewpoints
Olliaro, Piero L.
Kuesel, Annette C.
Halleux, Christine M.
Sullivan, Mark
Reeder, John C.
Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years
title Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years
title_full Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years
title_fullStr Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years
title_full_unstemmed Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years
title_short Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years
title_sort creative use of the priority review voucher by public and not-for-profit actors delivers the first new fda-approved treatment for river blindness in 20 years
topic Viewpoints
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237288/
https://www.ncbi.nlm.nih.gov/pubmed/30439940
http://dx.doi.org/10.1371/journal.pntd.0006837
work_keys_str_mv AT olliaropierol creativeuseofthepriorityreviewvoucherbypublicandnotforprofitactorsdeliversthefirstnewfdaapprovedtreatmentforriverblindnessin20years
AT kueselannettec creativeuseofthepriorityreviewvoucherbypublicandnotforprofitactorsdeliversthefirstnewfdaapprovedtreatmentforriverblindnessin20years
AT halleuxchristinem creativeuseofthepriorityreviewvoucherbypublicandnotforprofitactorsdeliversthefirstnewfdaapprovedtreatmentforriverblindnessin20years
AT sullivanmark creativeuseofthepriorityreviewvoucherbypublicandnotforprofitactorsdeliversthefirstnewfdaapprovedtreatmentforriverblindnessin20years
AT reederjohnc creativeuseofthepriorityreviewvoucherbypublicandnotforprofitactorsdeliversthefirstnewfdaapprovedtreatmentforriverblindnessin20years

Ejemplares similares